IN2014MN02518A - - Google Patents

Info

Publication number
IN2014MN02518A
IN2014MN02518A IN2518MUN2014A IN2014MN02518A IN 2014MN02518 A IN2014MN02518 A IN 2014MN02518A IN 2518MUN2014 A IN2518MUN2014 A IN 2518MUN2014A IN 2014MN02518 A IN2014MN02518 A IN 2014MN02518A
Authority
IN
India
Prior art keywords
host cells
ssi
cho
stable
produce
Prior art date
Application number
Other languages
English (en)
Inventor
James Rance
Robert Young
Michael J Agostino
Mark Moffat
Lin Zhang
Baohong Zhang
Original Assignee
Lonza Biologics Plc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics Plc, Pfizer filed Critical Lonza Biologics Plc
Publication of IN2014MN02518A publication Critical patent/IN2014MN02518A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2518MUN2014 2012-06-22 2013-06-20 IN2014MN02518A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663147P 2012-06-22 2012-06-22
EP12185330.3A EP2711428A1 (en) 2012-09-21 2012-09-21 Site-specific integration
PCT/EP2013/062859 WO2013190032A1 (en) 2012-06-22 2013-06-20 Site-specific integration

Publications (1)

Publication Number Publication Date
IN2014MN02518A true IN2014MN02518A (pt) 2015-07-17

Family

ID=46888327

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2518MUN2014 IN2014MN02518A (pt) 2012-06-22 2013-06-20

Country Status (19)

Country Link
US (2) US10280436B2 (pt)
EP (2) EP2711428A1 (pt)
JP (1) JP6053923B2 (pt)
KR (1) KR101761709B1 (pt)
CN (1) CN104379753B (pt)
AU (1) AU2013279333C1 (pt)
BR (1) BR112014032299B1 (pt)
CA (1) CA2876280C (pt)
DK (1) DK2864489T3 (pt)
EA (1) EA034039B1 (pt)
ES (1) ES2629509T3 (pt)
HK (1) HK1202580A1 (pt)
IL (1) IL236347A0 (pt)
IN (1) IN2014MN02518A (pt)
MX (1) MX351727B (pt)
PL (1) PL2864489T3 (pt)
SG (1) SG11201408576QA (pt)
TW (1) TWI523946B (pt)
WO (1) WO2013190032A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3693469A1 (en) * 2015-04-27 2020-08-12 Momenta Pharmaceuticals, Inc. Method of manufacturing a therapeutic protein
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
EP3445780A1 (en) 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
CA3015389A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
US20200002727A1 (en) * 2017-02-17 2020-01-02 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
WO2018150271A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
GB201703418D0 (en) * 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
CN107557390A (zh) * 2017-09-18 2018-01-09 江南大学 一种筛选cho细胞系高表达位点的方法
WO2020072480A1 (en) * 2018-10-01 2020-04-09 Lonza Ltd Ssi cells with predictable and stable transgene expression and methods of formation
CN113631711A (zh) * 2018-12-21 2021-11-09 豪夫迈·罗氏有限公司 核酸的靶向整合
WO2020204055A1 (ja) * 2019-04-02 2020-10-08 中外製薬株式会社 標的特異的な外来遺伝子の導入方法
EP4058583A1 (en) 2019-11-14 2022-09-21 Lonza Ltd. Methods of cell selection
KR102335242B1 (ko) 2020-05-22 2021-12-02 인천대학교 산학협력단 Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
WO2023012627A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE69840439D1 (de) 1997-04-24 2009-02-26 Univ Washington Zielgerichtete genveraenderung mit parvoviralen vektoren
EP1771483A1 (en) * 2004-07-20 2007-04-11 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
JP4665115B2 (ja) * 2004-08-06 2011-04-06 独立行政法人理化学研究所 骨・関節疾患感受性遺伝子およびその用途
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences

Also Published As

Publication number Publication date
JP2015519914A (ja) 2015-07-16
PL2864489T3 (pl) 2017-09-29
KR20150029693A (ko) 2015-03-18
ES2629509T3 (es) 2017-08-10
CA2876280C (en) 2018-02-06
SG11201408576QA (en) 2015-03-30
AU2013279333A1 (en) 2015-02-12
HK1202580A1 (en) 2015-10-02
IL236347A0 (en) 2015-02-26
CN104379753B (zh) 2020-06-09
MX2014015612A (es) 2015-07-14
AU2013279333B2 (en) 2017-03-30
EA201590068A1 (ru) 2015-04-30
US20150167020A1 (en) 2015-06-18
BR112014032299A2 (pt) 2017-08-01
US20190119702A1 (en) 2019-04-25
AU2013279333B9 (en) 2017-06-29
AU2013279333C1 (en) 2017-08-31
KR101761709B1 (ko) 2017-07-26
CA2876280A1 (en) 2013-12-27
MX351727B (es) 2017-10-26
JP6053923B2 (ja) 2016-12-27
TW201420762A (zh) 2014-06-01
DK2864489T3 (en) 2017-07-17
BR112014032299B1 (pt) 2021-09-21
US10280436B2 (en) 2019-05-07
EP2864489A1 (en) 2015-04-29
CN104379753A (zh) 2015-02-25
EP2864489B1 (en) 2017-03-29
EA034039B1 (ru) 2019-12-20
EP2711428A1 (en) 2014-03-26
WO2013190032A1 (en) 2013-12-27
US11326185B2 (en) 2022-05-10
TWI523946B (zh) 2016-03-01

Similar Documents

Publication Publication Date Title
IN2014MN02518A (pt)
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
PH12018501839A1 (en) St2l antagonists and methods of use
CR20140463A (es) Compuestos de heterociclilo como inhibidores de mek
MX363193B (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
UY34824A (es) Nucleósidos de espirooxetano de uracilo
EP2865656A4 (en) METHOD FOR MANUFACTURING GLASS PLATE HAVING CURVED PART AND GLASS PLATE HAVING CURVED PART
MX2020002544A (es) Sales de glicopirrolato.
ZA201401613B (en) Method for producing highly pure platinum powder, as well as platinum powder that can be obtained according to said method, and use thereof
PH12016500598A1 (en) Protoxin-ii variants and methods of use
IN2013DE00266A (pt)
PL3042880T3 (pl) Sposób wytwarzania płyty szklanej
MX2015015148A (es) Proceso para la preparacion de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos en una cascada de reactores.
ZA201600098B (en) Plant produced human papillomavirus pseudovirion
EP2971288A4 (en) COMPOSITIONS, METHODS, AND COMPUTER SYSTEMS ASSOCIATED WITH THE PRODUCTION AND ADMINISTRATION OF MODIFIED T CELLS
BR112014029620A2 (pt) unidade de ventilação
EP3022293A4 (en) Methods for modeling chinese hamster ovary (cho) cell metabolism
BR112015002145A2 (pt) pino intramedular
MX2019002801A (es) Uso de una composicion farmaceutica que comprende un anticuerpo anti-il-4r en el tratamiento de la dermatitis atopica.
IN2013MU01918A (pt)
GB201321642D0 (en) Technique to enhance the coincidence of focussed, converging, light beams
MX2016001694A (es) Formulacion de vacuna de sacarido.
GT201200007S (es) Dispositivo para iluminacion exterior (no.1)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
AU347876S (en) Adjustable spring base